21:17 , Dec 14, 2018 |  BC Week In Review  |  Company News

Veteran Roche cancer executive O'Day to lead Gilead

Daniel O’Day will inherit a pile of cash and a company that is looking beyond infectious disease to carve out its space in cancer and build on its newly acquired CAR T platform when he...
20:23 , Dec 10, 2018 |  BC Extra  |  Company News

Veteran Roche cancer executive O'Day to lead Gilead

Daniel O’Day will inherit a pile of cash and a company that is looking beyond infectious disease to carve out its space in cancer and build on its newly acquired CAR T platform when he...
23:53 , Nov 30, 2018 |  BC Extra  |  Clinical News

Trial registry shows He targeting PCSK9 in human embryos

Chinese scientist Jiankui He is conducting a second germline gene editing trial using CRISPR to target PCSK9 in human embryos, according to a retrospective clinical trial listing on the Chinese clinical trial registry. Chinese researchers...
00:25 , Nov 30, 2018 |  BC Extra  |  Politics & Policy

Summit committee issues call to define path to clinical germline editing

The organizing committee of the Second International Summit on Human Genome Editing said the time has come to define "a rigorous, responsible translational pathway" towards the clinical practice of germline editing. The pathway should include...
22:09 , Nov 28, 2018 |  BC Extra  |  Clinical News

Critics continue to pile on as CRISPR researcher describes informed consent, review process

Jiankui He outlined the peer review and informed consent process used in the first-ever human CRISPR germline gene editing trial at the International Summit on Human Genome Editing on Wednesday. However, critics decried the process...
01:37 , Aug 10, 2018 |  BC Innovations  |  Finance

Super-sized ambitions

A trend toward super-sized initial financings is attracting a new set of deep-pocketed investors to the early stage space. These new players are making earlier commitments with hopes of guaranteeing larger ownership positions at an...
03:02 , Jun 30, 2018 |  BioCentury  |  Finance

Smitten by SMID-caps

Risk is pervasive heading into the third quarter and choppy waters are expected, but 13 buysiders told BioCentury they’re not afraid to stay the course. A politically charged environment is likely to intensify as the...
02:00 , Oct 28, 2017 |  BioCentury  |  Strategy

Biogen doubles down

Shares of Biogen Inc. were buffeted last week by a pair of poorly understood moves intended to improve the big biotech’s share of profits for aducanumab, along with lower than expected revenues for newly launched...
17:09 , Sep 29, 2017 |  BioCentury  |  Strategy

Agios’ acceleration

A biomarker-driven strategy in a setting where response was easy to measure, along with a healthy pile of cash, allowed Agios Pharmaceuticals Inc. to go from concept to marketed drug in just over eight years....
10:21 , Aug 24, 2017 |  BC Innovations  |  Product R&D

MedImmune's neo stimulus package

The MedImmune LLC unit of AstraZeneca plc thinks its pipeline of immune stimulators will give it an edge in the crowded field of neoantigen cancer vaccines. The company's strategy raises the question of whether the...